M. Simeoni

发表

M. Simeoni, F. Vespasiano, 2013 .

Population Pharmacokinetic Modelling for Estimation of Remifentanil Metabolic-Ratio Using Non-steady-State Concentrations under Rapidly Adaptive Dosing

M. Simeoni, Chao Chen, Chao Chen, 2018, Pharmaceutical Research.

Title Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK 249320 Versus Placebo in Stroke Patients

Lori A. Enney, M. Simeoni, C. Russell, 2017 .

First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study

T. Fladby, H. Zetterberg, A. Wallin, 2015, PloS one.

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

P. A. Harris, J. Bertin, A. Verticelli, 2017, Pharmacology research & perspectives.

Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma

Shuying Yang, M. Simeoni, M. Beerahee, 2022, Clinical pharmacology and therapeutics.

A pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development.

G. De Nicolao, F. Fiorentini, E. Pesenti, 2005, Basic & clinical pharmacology & toxicology.

A PK-PD model for predicting tumor growth inhibition in mice: a useful tool in oncology drug development

G. Nicolao, F. Fiorentini, E. Pesenti, 2004 .

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase IIa study

K. Reich, C. Griffiths, M. Binks, 2016, The British journal of dermatology.

A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor

R. Prinjha, P. Soden, W. Fahy, 2021, British journal of clinical pharmacology.

MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues

S. M. Lavezzi, G. De Nicolao, S. Zamuner, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

A Morbid Democracy: Old and New Populisms

M. Simeoni, K. McCarthy, 2014 .

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

J. Bertin, K. Papp, D. Tompson, 2020, Clinical pharmacology and therapeutics.

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

Paolo Magni, Giuseppe De Nicolao, Monica Simeoni, 2004, Cancer Research.

Predicting the active doses in humans from animal studies: a novel approach in oncology.

M Rocchetti, G. De Nicolao, E. Pesenti, 2007, European journal of cancer.

Tumor growth modelling for drug development

G. Nicolao, P. Magni, M. Rocchetti, 2014 .

A mathematical model to study the effects of drugs administration on tumor growth dynamics.

M Rocchetti, P Magni, G. Nicolao, 2006, Mathematical biosciences.

stroke recovery Safety , Pharmacokinetics , and Pharmacodynamics of Escalating Repeat Doses of GSK 249320 in Patients With Stroke

S. Cramer, Lori A. Enney, M. Simeoni, 2012 .

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients

S. Cramer, Lori A. Enney, M. Simeoni, 2017, Stroke.

First‐Time‐in‐Human Study With GSK249320, a Myelin‐Associated Glycoprotein Inhibitor, in Healthy Volunteers

M. Simeoni, E. Cunningham, B. Abila, 2013, Clinical pharmacology and therapeutics.

Modeling Alzheimer’s disease progression using the disease system analysis approach

Michael Gold, Monica Simeoni, M. Irizarry, 2012, Alzheimer's & Dementia.

Modeling of human tumor xenografts and dose rationale in oncology.

Paolo Magni, Giuseppe De Nicolao, Monica Simeoni, 2013, Drug discovery today. Technologies.

A Minimal Model of Tumor Growth Inhibition

Giuseppe De Nicolao, Paolo Magni, Monica Simeoni, 2008, IEEE Transactions on Biomedical Engineering.

Population modeling of tumor growth inhibition in vivo: application to anticancer drug development

G. Nicolao, M. Rocchetti, I. Poggesi, 2004 .

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

H. Zetterberg, N. Andreasen, C. V. von Arnim, 2014, Alzheimer's Research & Therapy.

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase IIa study

K. Reich, M. Binks, M. Simeoni, 2016, The British journal of dermatology.

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

G. De Nicolao, P. Magni, V. Croci, 2004, Cancer Research.

A minimal model describing the effect of drug administration on tumor growth dynamics

G. De Nicolao, G. De Nicolao, P. Magni, 2006, 2006 14th Mediterranean Conference on Control and Automation.

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke

S. Cramer, Lori A. Enney, M. Simeoni, 2013, Stroke.